Print Page  |  Close Window


Please stop back for additional upcoming events. Thank you for your interest.

Corporate Profile

Neos Therapeutics develops, manufactures, and commercializes innovative extended-release (XR) products using our proprietary extended-release drug delivery and orally disintegrating tablet (ODT) technology platforms. We have two FDA approved products for the treatment of ADHD and both utilize our extended-release ODT technology. Our third branded ADHD product candidate is an extended-release oral suspension. Our growing ADHD Product Portfolio puts Neos in a unique position to meet the different needs of patients that struggle with ADHD.

News Releases

» READ MORE Neos Therapeutics News